Interview 31 May 2017 Poll: Academia, Biotech or Another Career? How Industry Leaders Decided Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […] May 31, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira Meet the founder of three hot British biotechs developing antibody-related technologies. Despite his interest in business, he remains an academic at heart. Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first company in […] May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 UK biotech is catching up to the US, but will it run out of gas? The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […] May 24, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 18 May 2017 #Live# Labiotech Hangout: Join our first webcast on anti-aging therapies! As we grow as a company, our content is growing too! Hang out with us and anti-aging VC managing partner, James Peyer, online next week. Join Now! We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week, we’re trying out a new feature and bringing additional […] May 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Heptares receives €4.5M Milestone for New Migraine Drug Candidate The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […] May 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 15 May 2017 Meet the CEO developing the Next Generation of Antibody Therapeutics Crescendo Biologics has positioned itself as the successor of Cambridge Antibody Technology and a new rival to Morphosys. We interviewed CEO Peter Pack. Peter Pack started working in life science 25 years ago — “quite a long time ago,” he laughs. “I’m an old guy now.” Now the CEO of Crescendo Biologics, whose Humabody platform […] May 15, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […] May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2017 Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR Synbio startup Oxford Genetics has licensed CRISPR from Emmanuelle Charpentier’s company, ERS Genomics, to boost its platform. Synthetic biology has so far remained on the fringe of biotech, but one company, Oxford Genetics, is demonstrating its use in therapeutics. To bolster its efforts, the startup has secured a nonexclusive license from ERS Genomics, which represents […] May 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 10 May 2017 Video: Meet the CEO fighting Cancer with Mycobacteria Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […] May 10, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 10 May 2017 Incentivizing Charity: A New Way to Fund Cancer Research Here’s what we learned from a lecture by finance guru Roger Stein on a new cancer research funding model at the Charité BIH Entrepreneurship Summit in Berlin. “I’m not a scientist. I can’t build a drug. I’m never going to have enough money to fund even one of those [clinical] trials. But…all of us together […] May 10, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 9 May 2017 Video Interview: Meet the Oxford COO improving Tech Transfer Adam Stoten is the new COO of Oxford University Innovation. Philip caught up with him at BioTrinity in London to talk about tech transfer. Both from academic and industrial perspectives, tech transfer has a reputation for being an onerous process. But some organizations are working steadfastly to streamline it with great success, like Oxford University Innovation. […] May 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 3 May 2017 German Pharma Investigates Genetics of Pain to Personalize Treatment At the height of the opioid epidemic, Grünenthal has partnered up with 23andMe to explore the genetic factors associated with pain. Though opioid abuse has not been as rampant in Europe as it has in the United States, German pharma Grünenthal, which focuses on pain, inflammation and gout, has staked out a position in the fight. Today, […] May 3, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email